SS
CYTK icon

Steve Schonfeld’s Cytokinetics CYTK Stock Holding History

Steve Schonfeld’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.55M Sell
53,354
-48,211
-47% -$3.46M 0.02% 680
2026
Q1 		$6.69M Buy
+101,565
New +$6.45M 0.05% 407
2025
Q2 		– Sell
-175,478
Closed -$7.05M – 2131
2025
Q1 		$7.05M Buy
+175,478
New +$8.06M 0.04% 422
2024
Q3 		– Sell
-15,699
Closed -$851K – 2110
2024
Q2 		$851K Sell
15,699
-23,915
-60% -$1.44M 0.01% 1278
2024
Q1 		$2.78M Buy
39,614
+35,650
+899% +$2.76M 0.02% 875
2023
Q4 		$331K Sell
3,964
-9,917
-71% -$359K ﹤0.01% 1401
2023
Q3 		$409K Sell
13,881
-16,936
-55% -$564K ﹤0.01% 1255
2023
Q2 		$1.01M Buy
30,817
+3,383
+12% +$125K 0.01% 973
2023
Q1 		$965K Sell
27,434
-29,427
-52% -$1.2M 0.01% 976
2022
Q4 		$2.61M Buy
+56,861
New +$2.45M 0.02% 715
2022
Q3 		– Sell
-79,366
Closed -$3.12M – 3000
2022
Q2 		$3.12M Buy
79,366
+71,166
+868% +$2.87M 0.03% 613
2022
Q1 		$302K Sell
8,200
-93,500
-92% -$3.32M ﹤0.01% 1692
2021
Q4 		$4.63M Buy
101,700
+22,184
+28% +$856K 0.04% 486
2021
Q3 		$2.84M Buy
79,516
+59,216
+292% +$1.74M 0.03% 598
2021
Q2 		$402K Buy
+20,300
New +$477K ﹤0.01% 1302
2020
Q2 		– Sell
-13,263
Closed -$156K – 1296
2020
Q1 		$156K Buy
+13,263
New +$169K 0.01% 952
2016
Q4 		– Sell
-20,000
Closed -$184K – 563
2016
Q3 		$184K Buy
+20,000
New +$209K 0.03% 370

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's CYTK Position: Q2 2026 in Review

Steve Schonfeld reduced its Cytokinetics (CYTK) stake by 47% in Q2 2026, selling an estimated $3.46M and leaving 53,354 shares worth $4.55M. The position accounts for 0.02% of the portfolio, ranked #680.

Steve Schonfeld first reported a position in CYTK in Q3 2016 and has held it in 17 quarters since. The position peaked at $7.05M in Q1 2025. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Steve Schonfeld held 53,354 shares of Cytokinetics worth $4.55M as of Q2 2026.
  • Steve Schonfeld sold 48,211 Cytokinetics shares in Q2 2026, an estimated $3.46M.
  • Cytokinetics made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #680 holding.
  • Steve Schonfeld first reported a position in Cytokinetics in Q3 2016 and has held it in 17 quarters since.
  • Steve Schonfeld's Cytokinetics position peaked at $7.05M in Q1 2025.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.